Abstract

Objectives

Lung carcinoids and atypical hamartomas may be difficult to differentiate but require different treatment. The aim was to differentiate these tumors using contrast-enhanced CT semantic and radiomics criteria.

Methods

Between November 2009 and June 2020, consecutives patient operated for hamartomas or carcinoids with contrast-enhanced chest-CT were retrospectively reviewed. Semantic criteria were recorded and radiomics features were extracted from 3D segmentations using Pyradiomics. Reproducible and non-redundant radiomics features were used to training a random forest algorithm with cross-validation. A validation-set from another institution was used to evaluate of the radiomics signature, the 3D ‘median’ attenuation feature (3D-median) alone and the mean value from 2D-ROIs.

Results

Seventy-three patients (median 58 years [43‒70]) were analyzed (16 hamartomas; 57 carcinoids). The radiomics signature predicted hamartomas vs carcinoids on the external dataset (22 hamartomas; 32 carcinoids) with an AUC = 0.76. The 3D-median was the most important in the model. Density thresholds < 10 HU to predict hamartoma and > 60 HU to predict carcinoids were chosen for their high specificity > 0.90. On the external dataset, sensitivity and specificity of the 3D-median and 2D-ROIs were, respectively, 0.23, 1.00 and 0.13, 1.00 < 10 HU; 0.63, 0.95 and 0.69, 0.91 > 60 HU. The 3D-median was more reproducible than 2D-ROIs (ICC = 0.97 95% CI [0.95‒0.99]; bias: 3 ± 7 HU limits of agreement (LoA) [− 10‒16] vs. ICC = 0.90 95% CI [0.85‒0.94]; bias: − 0.7 ± 21 HU LoA [− 4‒40], respectively).

Conclusions

A radiomics signature can distinguish hamartomas from carcinoids with an AUC = 0.76. Median density < 10 HU and > 60 HU on 3D or 2D-ROIs may be useful in clinical practice to diagnose these tumors with confidence, but 3D is more reproducible.

Critical relevance statement

Radiomic features help to identify the most discriminating imaging signs using random forest. ‘Median’ attenuation value (Hounsfield units), extracted from 3D-segmentations on contrast-enhanced chest-CTs, could distinguish carcinoids from atypical hamartomas (AUC = 0.85), was reproducible (ICC = 0.97), and generalized to an external dataset.

Key points

• 3D-‘Median’ was the best feature to differentiate carcinoids from atypical hamartomas (AUC = 0.85).

• 3D-‘Median’ feature is reproducible (ICC = 0.97) and was generalized to an external dataset.

• Radiomics signature from 3D-segmentations differentiated carcinoids from atypical hamartomas with an AUC = 0.76.

• 2D-ROI value reached similar performance to 3D-‘median’ but was less reproducible (ICC = 0.90).

Details

Title
Best imaging signs identified by radiomics could outperform the model: application to differentiating lung carcinoid tumors from atypical hamartomas
Author
Habert, Paul 1   VIAFID ORCID Logo  ; Decoux, Antoine 2 ; Chermati, Lilia 3 ; Gibault, Laure 4 ; Thomas, Pascal 5 ; Varoquaux, Arthur 6 ; Le Pimpec-Barthes, Françoise 7 ; Arnoux, Armelle 8 ; Juquel, Loïc 9 ; Chaumoitre, Kathia 3 ; Garcia, Stéphane 9 ; Gaubert, Jean-Yves 10 ; Duron, Loïc 11 ; Fournier, Laure 12 

 Aix Marseille University, Imaging Department, Hopital Nord, APHM, Marseille, France (GRID:grid.5399.6) (ISNI:0000 0001 2176 4817); Aix Marseille Univ, LIIE, Marseille, France (GRID:grid.5399.6) (ISNI:0000 0001 2176 4817); Université Paris Cité, PARCC UMRS 970, INSERM, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602) 
 Université Paris Cité, PARCC UMRS 970, INSERM, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602) 
 Aix Marseille University, Imaging Department, Hopital Nord, APHM, Marseille, France (GRID:grid.5399.6) (ISNI:0000 0001 2176 4817) 
 Publique Hôpitaux de Paris, Department of Pathology, Hôpital Européen Georges Pompidou, Assistance, Paris, France (GRID:grid.414093.b) (ISNI:0000 0001 2183 5849) 
 Aix Marseille Université, Service de Chirurgie Thoracique et Transplantation Pulmonaire, Hôpital Nord, Chemin des Bourrely, Marseille, France (GRID:grid.5399.6) (ISNI:0000 0001 2176 4817) 
 Aix-Marseille University, Department of Radiology, La Conception Hospital, Assistance Publique-Hôpitaux de Marseille, Marseille, France (GRID:grid.5399.6) (ISNI:0000 0001 2176 4817) 
 Université Paris Cité, Service de Chirurgie Thoracique Hopital Européen Georges Pompidou, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602) 
 Université Paris Cité, AP-HP, Hopital Européen Georges Pompidou, Unité de Recherche Clinique, Centre d’Investigation Clinique 1418 Épidémiologie Clinique, INSERM, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602) 
 Hôpital Nord, Service d’anatomie et Cytologie Pathologiques, Marseille, France (GRID:grid.414244.3) (ISNI:0000 0004 1773 6284); Aix Marseille Université, U1068-CRCM, Marseille, France (GRID:grid.5399.6) (ISNI:0000 0001 2176 4817) 
10  Aix Marseille Univ, LIIE, Marseille, France (GRID:grid.5399.6) (ISNI:0000 0001 2176 4817); Hôpital La Timone, Department of Radiology, AP-HM, Marseille, France (GRID:grid.411266.6) (ISNI:0000 0001 0404 1115) 
11  Université Paris Cité, PARCC UMRS 970, INSERM, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602); Alphonse de Rothschild Foundation Hospital, Department of Neuroradiology, Paris, France (GRID:grid.419339.5) 
12  Université Paris Cité, AP-HP, Hopital Européen Georges Pompidou, PARCC UMRS 970, INSERM, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602) 
Pages
148
Publication year
2023
Publication date
Dec 2023
Publisher
Springer Nature B.V.
e-ISSN
18694101
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2866251880
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.